Scynexis Receives FDA Designations for Antifungal Therapy SCY-247

Scynexis has received FDA designations for its antifungal therapy, SCY-247, indicating significant potential in treating fungal infections. The company plans clinical trials for both IV and oral formulations by 2026 and is exploring non-dilutive funding to support development. Scynexis has faced challenges in revenue growth and exhibits a strong liquidity position but has a high risk of bankruptcy. The company's valuation metrics suggest a potentially undervalued position.